Victory Capital Management Inc. lifted its position in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 21.7% in the first quarter, HoldingsChannel reports. The firm owned 1,688,663 shares of the company’s stock after purchasing an additional 300,900 shares during the quarter. Victory Capital Management Inc.’s holdings in Apellis Pharmaceuticals were worth $32,929,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Flinton Capital Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Apellis Pharmaceuticals by 159.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,903 shares of the company’s stock worth $38,000 after purchasing an additional 1,785 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter worth about $112,000. BNP Paribas Arbitrage SA boosted its holdings in Apellis Pharmaceuticals by 250,533.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,519 shares of the company’s stock valued at $147,000 after acquiring an additional 7,516 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Apellis Pharmaceuticals by 35.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock valued at $124,000 after acquiring an additional 2,440 shares during the period. Hedge funds and other institutional investors own 51.74% of the company’s stock.
In other news, major shareholder Morningside Venture Investment bought 441,176 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was purchased at an average price of $17.00 per share, with a total value of $7,499,992.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 9.30% of the stock is currently owned by corporate insiders.
Several equities research analysts recently weighed in on APLS shares. Zacks Investment Research upgraded Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 4th. Cantor Fitzgerald set a $57.00 target price on Apellis Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. JPMorgan Chase & Co. cut Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 target price for the company. in a report on Wednesday, January 23rd. Finally, Robert W. Baird began coverage on Apellis Pharmaceuticals in a report on Thursday, March 28th. They issued an “outperform” rating and a $45.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $41.83.
NASDAQ APLS traded down $0.78 on Friday, hitting $17.75. The company’s stock had a trading volume of 182,883 shares, compared to its average volume of 414,727. Apellis Pharmaceuticals Inc has a 52-week low of $11.45 and a 52-week high of $24.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.23 and a current ratio of 15.23. The stock has a market cap of $1.17 billion, a P/E ratio of -7.59 and a beta of 0.44.
Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.20). Sell-side analysts predict that Apellis Pharmaceuticals Inc will post -3.18 earnings per share for the current year.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Further Reading: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.